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Abstract 
Concentrations of liver enzymes in plasma are widely used as indicators of liver disease. We carried out a 
genome-wide association study in 61,089 individuals, identifying 42 loci associated with concentrations of 
liver enzymes in plasma, of which 32 are new associations (P = 10−8 to P = 10−190). We used functional 
genomic approaches including metabonomic profiling and gene expression analyses to identify probable 
candidate genes at these regions. We identified 69 candidate genes, including genes involved in biliary 
transport (ATP8B1 and ABCB11), glucose, carbohydrate and lipid metabolism (FADS1, FADS2, GCKR, 
JMJD1C, HNF1A, MLXIPL, PNPLA3, PPP1R3B, SLC2A2 and TRIB1), glycoprotein biosynthesis and cell surface 
glycobiology (ABO, ASGR1, FUT2, GPLD1 and ST3GAL4), inflammation and immunity (CD276, CDH6, GCKR, 
HNF1A, HPR, ITGA1, RORA and STAT4) and glutathione metabolism (GSTT1, GSTT2 and GGT), as well as 
several genes of uncertain or unknown function (including ABHD12, EFHD1, EFNA1, EPHA2, MICAL3 and 
ZNF827). Our results provide new insight into genetic mechanisms and pathways influencing markers of 
liver function. 
 
 
High concentrations of liver enzymes in plasma are observed in liver injury caused by multiple insults 
including alcohol misuse, viral and other infections, metabolic disorders, obesity, autoimmune disease and 
drug toxicity. High liver enzyme concentrations are associated with increased risk of cirrhosis2, 
hepatocellular carcinoma3, type 2 diabetes4 and cardiovascular disease5. Abnormal liver function is a 
common reason for terminating new clinical therapeutic agents, representing a major challenge for the 
global pharmaceutical industry6. Liver enzyme concentrations in plasma are highly heritable7, suggesting 
an important role for genetic factors. 
We carried out a genome-wide association study (GWAS) in 61,089 research participants to identify genetic 
loci influencing liver function measured by concentrations of alanine transaminase (ALT), alkaline 
phosphatase (ALP) and γ-glutamyl transferase (GGT) in blood. ALT is mainly a marker of hepatocellular 
damage1, and may also be high in obesity and fatty liver disease8. ALP is a marker of biliary obstruction, 
and is also released from bone, intestine, leucocytes and other cells1. GGT is sensitive to most kinds of liver 
insult, particularly alcohol1. Our study design is summarized in Figure 1. Characteristics of participants, 
genotyping arrays and quality control measures are summarized in Supplementary Tables 1–4. Genome-
wide significance was inferred at P < 1 × 10−8, allowing a Bonferroni correction for ~106 independent SNPs 
tested9, and for three separate liver markers; the latter is a conservative adjustment given the correlations 
between concentrations of the three liver markers (r = 0.19–0.64) and their association test results (r = 
0.02–0.19; Supplementary Table 5). 
We found 1,304 SNPs associated with one or more liver markers at P < 1 × 10−7 across 42 genetic loci 
(Table 1 and Fig. 2). At 35 of these loci, one or more SNPs reached genome-wide significance (P < 1 × 10−8; 
Supplementary Table 6); at the other seven genetic loci, the top-ranking SNP reached genome-wide 
significance after further testing in an additional sample of 12,139 research participants (Supplementary 
Table 7). Regional plots for each of the genetic loci are shown in Supplementary Figures 1–3. Common 
variants at chromosome 8q24 were associated with both ALP and ALT, and variants at chromosome 19q13 
were associated with both ALP and GGT, at P < 1 × 10−8. Sixteen loci associated with one liver marker at P < 
10−8 showed additional associations with a second marker at P < 6 × 10−4 (corresponding to P < 0.05 after 
Bonferroni correction for testing 42 loci against two alternate liver markers; Supplementary Fig. 4 and 
Supplementary Table 8). The loci previously reported to be associated with liver markers in GWASs were 
replicated in the current study, except for variants at the ALDH2 locus reported in Japanese populations, 
which have low allele frequency in European populations10,11. 
We used coding variation, expression quantitative trait loci (eQTL) and GRAIL analyses to identify possible 
candidate genes at the 42 loci associated with liver enzymes (Table 1 and Supplementary Table 9). There 
are 19 nonsynonymous SNPs (nsSNPs) that are in linkage disequilibrium (LD) with one or more of the 
sentinel SNPs at r2 ≥ 0.5 in the HapMap phase II CEU data set12 (see URLs), representing a ~3.5-fold 
enrichment compared with the number expected under the null hypothesis (P = 0.004). We considered the 
gene containing the nsSNP to be a strong candidate when (i) the nsSNP and the sentinel SNPs were in LD (r2 
> 0.5) and (ii) there was no evidence for heterogeneity of effect on phenotype. The genes with coding 
variants identified as candidates for mediating the observed associations with liver markers 
(Supplementary Table 10) encode proteins involved in biliary transport (ATP8B1)13, cell surface 
glycobiology, endoplasmic trafficking and susceptibility to gastrointestinal infection (FUT2 and 
GPLD1)14,15, carbohydrate and lipid metabolism, including susceptibility to type 2 diabetes (GCKR, HNF1A 
and SLC2A2)16–18 and inflammation as measured by circulating concentrations of C-reactive protein (CRP) 
(GCKR and HNF1A)19. Mutations in ATP8B1 are responsible for progressive familial intrahepatic cholestasis 
and are associated with high GGT concentrations20; the coding variant identified is predicted to be 
nonconservative (Supplementary Fig. 5). At chromosome 14q32, rs944002 is in LD (r2 = 0.86) with two 
nsSNPs in C14orf73, a gene strongly expressed in liver. C14orf73 has strong sequence homology with SEC6, 
a protein that interacts with the actin cytoskeleton and vesicle transport machinery21. Of the two nsSNPs 
reported in C14orf73, p.Arg77Trp is predicted to be a nonconservative change from a polar basic residue to 
a nonpolar hydrophobic residue (Supplementary Fig. 5). 
We repeated the search for coding variants using available results from the 1000 Genomes Project22 (see 
URLs) and identified coding variants in two additional genes, NBPF3 (chromosome 1p36.12) and MLXIPL 
(chromosome 7q11). Both genes are separately implicated as candidates for genes mediating the 
associations of sentinel SNPs with liver markers through eQTL analyses. 
We examined the association of the sentinel SNPs with eQTL data from liver, fat and peripheral blood 
leucocytes23–25 (Supplementary Tables 11–14). We tested SNPs for association with expression of nearby 
(within 1 Mb) genes (at P < 0.05 after Bonferroni correction for number of SNP expression associations 
tested). When we identified probable eQTLs, we tested whether the sentinel SNP and the SNP most closely 
associated with the eQTL were coincident (r2 > 0.5 and absence of heterogeneity at the phenotype or 
eQTL). This strategy identified eQTLs at 23 of the 42 loci, representing genes implicated in glutathione 
metabolism and drug detoxification (GSTT1 and GGT1), carbohydrate and lipid metabolism (MLXIPL, 
PPP1R3B, FADS1 and FADS2), cell signaling (ABHD12 and EPHA2) and inflammation and immunity (STAT4, 
MAPK10, CD276 and HPR). The functions of the other candidate genes identified by eQTLs (including 
EFHD1, MICAL3, DENND2D, CEPT1, MLIP (also known as C6orf142) and RSG1 (also known as C1orf89)) are 
poorly understood. 
 We also carried out a literature analysis using the GRAIL algorithm26 (see URLs), initially using the 2006 
data set to avoid studies of the GWAS era. At chromosome 2q24, GRAIL identified ABCB11 as the most 
plausible candidate (Supplementary Table 15). ABCB11 activity is a major determinant of bile formation and 
bile flow27; mutations in ABCB11 cause progressive familial intra- hepatic cholestasis type 2 and are 
associated with increased risk of hepatocellular carcinoma28,29. We repeated the GRAIL analysis using the 
2010 PubMed data set. This also identified ABCB11 as the plausible candidate at chromosome 2q24 but 
additionally identified ABO, GCKR, MLXIPL and PNPLA3 as probable candidates at other loci (Supplementary 
Table 15), replicating our findings from coding variant and eQTL analyses. 
Through our coding variant, expression and GRAIL analyses, we identified 44 genes as strong candidates at 
the 42 loci associated with concentrations of liver enzymes in plasma. We also considered the gene nearest 
to the sentinel SNP at each locus to be a potential candidate. Together these approaches identified 69 
candidate genes. Pathway analyses showed subnetworks of closely interconnected genes (Supplementary 
Fig. 6) from core metabolic path- ways and processes including carbohydrate metabolism, insulin signaling 
and diabetes (GCKR, SLC2A2, PPP1R3B, FUT2, ALDOB, HNF1A and MLXIPL), lipid metabolism (CEPT1, FADS1, 
FADS2, HNF1A, PNPLA3 and ALDH5A1), glycosphingolipid biosynthesis and glycosylation (ST3GAL4, FUT2 
and ABO) and glutathione metabolism (ALDHA5, GGT1 and GSTT1). 
Of the 42 liver marker loci, 24 have been reported to be associated with other phenotypes in genome-wide 
studies (Supplementary Table 16). At 12 of the loci, the lead SNP for the liver marker and the phenotype 
are the same or in LD at r2 ≥ 0.5, suggesting shared biological pathways. The phenotypes include Crohn’s 
disease, pancreatic carcinoma, type 2 diabetes, waist circumference and concentrations of glucose, insulin, 
total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, fatty acids, 
uric acid and C-reactive protein. At other loci, the sentinel SNP from the liver marker GWAS and the lead 
SNP in the US National Human Genome Research Institute (NHGRI) catalog30 (see URLs) are in low LD, 
suggesting that these likely represent different underlying mechanisms. We also ascertained the 
relationships of the 42 loci with quantitative anthropometric and metabolic traits in published genome-
wide meta-analyses (Supplementary Table 17). We found that the loci associated with liver enzymes are 
enriched in SNPs associated with lipid concentrations, fasting glucose and inflammation as measured by 
CRP. 
We used metabonomic profiling, the systematic characterization of a metabolite panel, to better 
understand the relationships of the 42 liver enzyme loci with intermediary and lipoprotein metabolism. We 
carried out quantitative nuclear magnetic resonance (NMR) spectroscopy on serum samples from 6,516 
participants from the London Life Sciences Population31 (LOLIPOP) and Northern Finland Birth Cohort 1966 
(ref. 32; NFBC1966) studies. Significance was inferred at P < 1 × 10−5, corresponding to P < 0.05 after 
Bonferroni correction for the 42 independent SNPs tested, and for the 69 primary NMR measures. At 
chromosomes 2p23 (C2orf16 and GCKR) and 8q24 (TRIB1), effect alleles of the sentinel SNPs are associated 
with high very low-density lipoprotein, intermediate-density lipoprotein and LDL concentration and VLDL 
particle size, high lipoprotein triglyceride and cholesterol concentration, omega-3 and omega-6 fatty acid 
concentrations, and concentrations of metabolic substrates citrate, pyruvate and branch chain amino acids 
(Fig. 3). At chromosome 12q24 (HNF1A), rs7310409 is associated with lipoprotein concentration and 
composition, and with tyrosine concentrations. At chromosomes 11q12 (C11orf10, FADS1 and FADS2) and 
8p23 (PPP1R3B), the effect alleles are associated with low concentrations of cholesterol and HDL 
cholesterol and with low concentrations of omega-3 and other unsaturated fatty acids. Our results from the 
NMR confirm and extend previous studies using mass spectroscopy, which showed strong association of 
GCKR and FADS1 with absolute and relative abundances of polyunsaturated fatty acids33,34. 
We examined the contribution of the 42 genetic loci to concentrations of liver enzymes in plasma among 
the 8,112 participants of the LIFELINES population study35. SNPs at 41 loci showed consistent direction of 
effect (P = 4 × 10−13, sign test; Supplementary Table 18). Together the SNPs associated with each liver 
enzyme account for 0.1%, 3.5% and 1.9% of population variation in plasma concentrations of ALT, ALP and 
GGT, respectively (Supplementary Table 19). We then constructed a SNP score as the unweighted sum of 
the effect allele counts for the SNPs associated with each liver marker. Participants in the top quartile of 
distribution for SNP score for ALT, ALP or GGT were ~1.4, ~2.4 and ~1.8 times more probable to have 
greater than the upper limit of normal concentrations of ALT, ALP and GGT, and on average had 
concentrations of ALT, ALP and GGT that were 7%, 13% or 26% higher, respectively, than participants in the 
lowest quartile of SNP score (Supplementary Table 19). 
Finally we tested the relationship of the liver enzyme–associated loci with the presence of structural 
changes in the liver indicative of hepatic steatosis, as determined by computerized axial tomography (CT) 
scanning in a population sample of 9,610 participants of the Genetics of Liver Disease (GOLD) study36. SNPs 
at five loci were associated with hepatic steatosis at P < 0.05, including PNPLA3, PPP1R3B, GCKR, TRIB1, 
HNF1A and SOX9 loci (Supplementary Table 20); of these, PNPLA3, PPP1R3B and GCKR were associated 
with hepatic steatosis at P < 0.0012 (that is, P < 0.05 after Bonferroni correction for 42 loci). 
We identify 42 independent loci associated with ALP, ALT or GGT and 69 genes as candidates for the 
associations observed (Supplementary Table 9). The candidate genes include ATP8B1 and ABCB11, 
encoding biliary transporters with a key role in bile formation and flow20,37, and many genes involved in 
carbohydrate and lipid metabolism, including GCKR, MLXIPL, SLC2A2, HNF1A, PNPLA3, FADS1, FADS2 and 
PPP1R3B17,38,39. PNPLA3, PPP1R3B and GCKR influence accumulation of hepatic triglycerides40,41. We 
identify GSTT1, GSTT2 and GGT as candidates encoding key enzymes in glutathione synthesis and drug 
metabolism42,43; these observations may be relevant to pharmacogenetics and drug development. We 
also identify a set of genes involved in inflammation and immunity, including CD276, CDH6, GCKR, HPR, 
ITGA1, MAPK10, RORA and STAT4. Whether these genes influence hepatic inflammatory responses to 
accumulation of triglycerides, viral infection or other exogenous challenges remains to be determined. 
Finally we identify a set of genes involved in glycoprotein biology, including ABO, ASGR1, FUT2, GPLD1 and 
ST3GAL4. The products of these genes influence synthesis, cell surface binding and turnover of 
glycoproteins. These pathways are linked to susceptibility to pancreatic44 and gastric malignancy45, 
intestinal and other infections46 and vitamin B12 metabolism47. The pleiotropic nature of the genes we 
identified suggests that their relationships with ALP, ALT or GGT may also be mediated by pathways 
operating outside of the liver. 
In summary, we report a GWAS for concentrations of liver enzymes in plasma, providing new insight into 
the genetic variation and pathways influencing ALP, ALT and GGT. Our findings provide the basis for further 
studies investigating the biological mechanisms involved in liver injury. 
 
METHODS 
Participants 
 
Genome-wide association was done among 61,089 participants from the following published studies: the 
Australian Twin cohort (n = 425)48; the British Genetics of Hypertension study (BRIGHT, n = 1,955)49; the 
Lausanne Cohort (CoLaus, n = 5,636)50; deCODE genetics (n = 12,572)51; the Fenland study (n = 1,397)52; 
the Finnish Twin cohort study (FinnTwin, n = 32)53; the Framingham Heart Study (n = 2,869)54; the 
Monica/KORA Augsburg study (KORA, n = 1,809)55; the London Life Sciences Population study (LOLIPOP, n 
= 10,338)31; the Northern Finland Birth Cohort 1966 (NFBC1966, n = 4,562)32; the Netherlands Study of 
Depression and Anxiety (NESDA, n = 1,724)56; the Netherlands Twin study (n = 1,721)57; the Precocious 
Coronary Artery Disease study (Procardis, n = 1,239)58; the Rotterdam Study 1 (RS1, n = 4,312)59; the 
SardiNIA study (n = 4,302)60; the Study of Health in Pomerania (SHIP, n = 4,101)61 and the TwinsUK study 
(n = 2,256)62. Sample sizes for ALT, ALP and GGT genome-wide analyses were 45,596, 56,415 and 61,089, 
respectively. Further characteristics of the genome-wide association cohorts are listed in Supplementary 
Note and Supplementary Tables 1 and 2. SNPs showing equivocal association with liver markers were 
further tested among 12,139 participants from the LOLIPOP study, with none included in the genome-wide 
study (Supplementary Table 4). 
Genotyping and quality control 
Genome-wide association scans were done using Affymetrix, Illumina and Perlegen Sciences arrays 
(Supplementary Table 3). Imputation of missing genotypes was done using phased haplotypes from 
HapMap build36 and dbSNP build 126. Imputed SNPs with minor allele frequency < 0.01 or low-quality 
score (r2 < 0.30 in MACH, or information score <0.3 in IMPUTE) were removed. This generated ~2.6 million 
directly genotyped or imputed autosomal SNPs. Genotyping for further testing was done by KASPar (K-
Biosciences, LTD). 
Statistical analysis 
Plasma concentrations of ALT, ALP and GGT were log10 transformed to achieve approximate normality. 
SNPs were tested for association with liver markers by linear regression using an additive genetic model 
adjusted for age and sex. An additional term was included to indicate case status in case-control studies, 
and principal component scores (EIGENSTRAT63) were used to adjust for substructure in studies of 
unrelated individuals (Supplementary Table 3). Test statistics were corrected for respective genomic control 
inflation factor (Supplementary Table 4) to adjust for residual population structure. Association analyses 
were carried out separately in each cohort followed by meta-analysis using weighted z scores. Meta-
analysis P values were then corrected for the meta-analysis genomic control inflation factors. The GWAS 
had 80% power to detect SNPs associated with 0.1% of population variation in ALP and 0.06% of population 
variation in ALT and GGT at P < 5 × 10−7. 
In the replication samples, SNP associations were tested by linear regression using an additive genetic 
model and adjustment for age and sex. Results were combined with findings from the genome-wide 
association cohorts, using the weighted z scores. Genome-wide significance was inferred at P < 1 × 10−8. 
SNP effect sizes were estimated by inverse-variance meta-analysis in the genome-wide association cohorts 
and available replication cohorts using a fixed effects model. 
Coding variant analyses 
 
We identified coding SNPs within 1 Mb and in LD at r2 > 0.5 with the sentinel liver SNPs using HapMap CEU 
II genotype data (see URLs). We tested for enrichment by permutation testing using 42 randomly selected 
SNPs from the ~2.6 million genotyped or imputed SNPs studied that had similar minor allele frequency 
±0.02), number of nearby genes (±10%) and gene proximity (±20 kb) to the sentinel SNPs. We counted 
coding SNPs within 1 Mb and in LD at r2 > 0.5 of the random SNPs; this was repeated 1,000 times to 
generate a distribution for expected, against which we compared the number observed (n = 19, P = 0.004). 
We considered a coding SNP to be a strong candidate for the observed association when it was in LD at r2 > 
0.5 with the sentinel SNP, with no evidence for heterogeneity of effect on phenotype (P > 0.05). Using this 
approach, we identified 17 coding SNPs in 14 genes as candidates for mediating the observed associations 
with liver markers (Supplementary Table 10). We used PHYRE64 to model the molecular structure of the 
protein products and possible pathogenicity of the coding SNPs identified. 
Expression analyses 
The sentinel SNPs from the liver marker GWAS were tested for association with gene expression in 603 
adipose and 745 peripheral blood samples from Icelandic subjects25, peripheral blood lymphocytes from 
206 families of European descent (830 parents and offspring)23 and 960 human liver samples24. Sentinel 
SNPs were tested for association with transcript levels of genes within 1 Mb; significance was inferred at P 
< 0.05 after Bonferroni correction for number of SNP-transcript combinations tested. We then used the 
whole-genome genotype data to identify which SNP from the liver locus was most closely associated with 
the transcript of interest; we defined this as the transcript SNP. We tested whether the sentinel SNP and 
transcript SNP were coincident, defined as in LD at r2 > 0.5, with no evidence for heterogeneity of effect 
between the SNPs on transcript expression or liver marker phenotype. 
GRAIL 
We carried out a PubMed literature analysis using GRAIL (see URLs)65 including all 42 sentinel SNPs 
simultaneously. We used the 2006 PubMed data set as the primary analysis (Supplementary Table 15) but 
repeated the analysis using the 2010 PubMed data set. 
Network analyses 
Network analyses were carried out using the Ingenuity Pathway Analysis tool66. P values for canonical 
pathways and functions were calculated from the observed number of candidate genes in the gene set, 
compared with the number expected under the null hypothesis and corrected (Bonferroni) for the number 
of pathways tested. 
Overlap with other GWAS 
We used the NHGRI30 catalog (see URLs) to identify other phenotypic associations (P < 5 × 10−8) located 
within 1 Mb of a the SNPs we identified as associated with liver enzymes (Supplementary Table 16). 
Previous studies reporting genetic variants influencing concentrations of liver enzymes in plasma were 
excluded. Pairwise LD with the sentinel liver marker SNP was determined using HapMap 2 CEU genotype 
data. 
Phenotypic pleiotropy 
Relationships of the selected 42 sentinel SNPs with anthropometric and metabolic traits relevant to liver 
function were tested in the following genome-wide meta-analyses (Supplementary Table 17): AlcGen 
Consortium, alcohol consumption67; ICBP-GWAS, systolic and diastolic blood pressure68; the Genetics of C-
reactive Protein Study (CRP-Gen), C-reactive protein19; MAGIC, fasting glucose and related glycemic 
traits16; DIAGRAM+ Study, type 2 diabetes17; GIANT Consortium, body mass index69 and the Global Lipids 
Genetics Consortium, total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride concentrations70. 
Associations were tested in silico using results from the genome-wide association phase and adopting the 
phenotypic definitions applied in each study. We inferred association of SNP with phenotype at P < 0.0012, 
corresponding to P < 0.05 after Bonferroni correction for 42 loci. We tested whether phenotypes were 
enriched for association with liver marker SNPs using a binomial probability test. 
Metabonomic analyses 
We carried out quantitative NMR spectroscopy on serum samples from 2,269 LOLIPOP and 4,247 NFBC1966 
participants with genome-wide data to investigate the relationships of the identified loci with lipoprotein 
and intermediary metabolism. NMR assays were carried out using a Bruker AVANCE III spectrometer 
operating at 500.36 MHz (1H observation frequency; 11.74 T) and equipped with an inverse selective SEI 
probe-head including an automatic tuning and matching unit and a z-axis gradient coil for automated 
shimming71,72. A BTO-2000 thermocouple was used for temperature stabilization of the sample at ~0.01 
°C. The high-performance electronics enabled metabolite quantification without per-sample chemical 
referencing or double-tube systems. The NMR methodology provides information on lipoprotein subclass 
distribution and lipoprotein particle concentrations, low-molecular-mass metabolites such as amino acids, 
3-hydroxybutyrate and creatinine, and detailed molecular information on serum lipids including free and 
esterified cholesterol, sphingomyelin, saturation, unsaturation, polyunsaturation and omega-3 fatty 
acids73. Associations of SNPs with metabolic measures were tested in each cohort separately using an 
additive genetic model and were adjusted for age, gender and principal components. Results for LOLIPOP 
and NFBC1966 were combined by inverse variance meta-analysis, and significance was inferred at P < 1 × 
10−5 (corresponding to P < 0.05 after Bonferroni correction for the 42 independent SNPs tested and for 69 
primary NMR measures). 
Contribution of genetic loci identified to population variation in liver enzymes 
This was investigated in the LifeLines Cohort Study35, a prospective population-based cohort study of 
165,000 persons aged 18–90 living in The Netherlands, and independent of the genome-wide association 
discovery cohorts. Genotyping was carried out in representative samples of 8,112 participants (aged 47.8 ± 
11.2, body mass index 26.2 ± 4.3 kg/m2 (mean ± s.d.), 43% male) using the Illumina CytoSNP12 array, and 
imputation of missing HapMap2 genotypes was done using Beagle 3.1.0. Liver markers were measured on a 
Roche/Hitachi Modular System (Roche Diagnostics). Mean ± s.d. concentrations of liver markers were 23.8 
± 16.8, 62.8 ± 18.4 and 26.3 ± 24.5 IU/l for ALT, ALP and GGT, respectively. The contribution of SNPs to 
population variation in liver markers was examined individually and in aggregate (Supplementary Tables 18 
and 19). For the latter, SNP scores were calculated for each individual on the basis of the sum of effect 
(trait-raising) alleles present at each of the genetic loci identified. 
Liver imaging for hepatic steatosis 
 
Hepatic steatosis was assessed by CT scanning in 9,610 participants from four population cohorts primarily 
designed for investigation of cardiovascular disease and its risk factors, (i) AGES-Reykjavik (n = 4,772), (ii) 
the Amish study (n = 541), (iii) the Family Heart Study (n = 886) and (iv) the Framingham Study (n = 
3,411)36. CT measurements, blind to participant characteristics, were calibrated against phantoms and 
inverse normally transformed. Genome-wide SNP data were available in each cohort with imputation of 
missing genotypes. SNP association with hepatic steatosis was tested in each cohort separately by linear 
regression with age, with age2 and gender as covariates and taking relatedness into account. Results were 
combined by fixed-effect inverse-variance meta-analysis (Supplementary Table 20). 
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Fig1 
Summary of study design 
 
 
 
  
Fig2 
Manhattan plots of association of SNPs with ALT, ALP and GGT in the GWAS. SNPs reaching genome-wide 
significance (P < 1 × 10−8) are red; SNPs with P > 1 × 10−8 and P < 1 × 10−7 are green. 
 
  
Table 1 
Genetic loci associated with concentrations of liver enzymes in plasma at P < 1 × 10
−8
 in the 
GWAS 
Region 
Sentinel 
SNP Position 
Alleles 
(R/E) EAF 
Effect (%, 95% 
confidence 
interval) P Genes of interest 
ALT 
4q22 rs6834314 88,432,832 G/A 0.75 2.6 (1.9–3.4) 3.1 × 
10
−9
 
HSD17B13
ne
, 
MAPK10
e
 
8q24 rs2954021 126,551,259 G/A 0.50 1.6 (0.6–2.6) 5.3 × 
10
−9
 
TRIB1
n
 
10q24
a
 rs10883437 101,785,351 A/T 0.64 2.3 (1.4–3.1) 4.0 × 
10
−9
 
CPN1
n
 
22q13
a
 rs738409 42,656,060 C/G 0.23 6.0 (5.0–7.0) 1.2 × 
10
−45
 
PNPLA3
nc
, SAMM50
c
 
ALP 
1p36.12
a
 rs1976403 21,639,040 A/C 0.40 3.6 (3.0–4.2) 1.8 × 
10
−50
 
ALPL
o
, NBPF3
nce
 
2q24 rs16856332 169,548,820 G/T 0.96 3.9 (1.2–6.7) 1.6 × 
10
−9
 
ABCB11
ng
 
6p22
a
 rs1883415 24,599,454 A/C 0.33 3.1 (2.5–3.7) 5.6 × 
10
−26
 
ALDH5A1
e
, GPLD1
nc
 
8p23 rs6984305 9,215,678 T/A 0.11 2.7 (1.1–4.4) 2.1 × 
10
−10
 
PPP1R3B
ne
 
8q24 rs2954021 126,551,259 G/A 0.50 1.4 (0.5–2.3) 2.3 × 
10
−13
 
TRIB1
n
 
9q21 rs10819937 103,263,054 G/C 0.17 2.5 (1.4–3.6) 1.0 × 
10
−9
 
ALDOB
o
, C9orf125
n
 
9q34
a
 rs579459 135,143,989 C/T 0.80 8.8 (7.4–10.2) 2.6 × 
10
−123
 
ABO
n
 
10q21
a
 rs7923609 64,803,828 A/G 0.50 2.2 (1.7–2.7) 5.9 × 
10
−23
 
JMJD1C
nce
, NRBF2
e
 
11q12 rs174601 61,379,716 C/T 0.35 1.7 (0.8–2.6) 2.6 × 
10
−9
 
C11orf10
e
, FADS1
e
, 
FADS2
ne
 
11q.24 rs2236653 125,788,995 C/T 0.42 1.5 (0.6–2.5) 1.8 × 
10
−9
 
ST3GAL4
n
 
16q22 rs7186908 70,777,874 G/C 0.24 2.0 (1.1–2.9) 4.8 × 
10
−9
 
HPR
e
, PMFBP1
n
 
17p13 rs314253 7,032,374 T/C 0.33 2.1 (1.5–2.8) 8.4 × 
10
−12
 
ASGR1
o
, DLG4
n
 
19q13
a
 rs281377 53,898,415 C/T 0.43 1.8 (0.8–2.8) 1.1 × 
10
−15
 
FUT2
nc
 
20p11 rs7267979 25,246,087 A/G 0.57 1.5 (0.9–2.0) 7.4 × 
10
−10
 
ABHD12
ne
, GINS1
ce
, 
PYGB
o
 
Region 
Sentinel 
SNP Position 
Alleles 
(R/E) EAF 
Effect (%, 95% 
confidence 
interval) P Genes of interest 
GGT 
1p36.13 rs1497406 16,377,907 A/G 0.56 3.8 (2.7–4.8) 2.8 × 
10
−19
 
RSG1
e
, EPHA2
ne
 
1p22 rs12145922 88,918,822 C/A 0.61 2.8 (2.2–3.4) 3.8 × 
10
−11
 
CCBL2
e
, PKN2
n
 
1p13 rs1335645 111,485,799 G/A 0.88 4.3 (3.5–5.2) 7.3 × 
10
−9
 
CEPT1
ne
, 
DENND2D
e
 
1q21 rs10908458 153,393,572 C/T 0.58 3.7 (3.1–4.2) 1.7 × 
10
−15
 
DPM3
n
, EFNA1
ce
, 
PKLR
o
 
2p23 rs1260326 27,584,444 C/T 0.38 3.2 (2.4–4.0) 3.9 × 
10
−13
 
C2orf16
e
, GCKR
nc
 
2q12 rs13030978 191,825,483 C/T 0.32 3.7 (2.8–4.6) 1.1 × 
10
−11
 
MYO1B
ne
, STAT4
e
 
2q37 rs2140773 233,221,419 C/A 0.61 2.9 (2.3–3.5) 1.1 × 
10
−9
 
EFHD1
ne
, 
LOC100129166
c
 
3q26 rs10513686 172,208,236 G/A 0.14 4.9 (4.0–5.7) 6.1 × 
10
−11
 
SLC2A2
nc
 
4q31 rs4547811 147,014,071 T/C 0.18 6.4 (5.0–7.9) 2.5 × 
10
−27
 
ZNF827
n
 
5p15 rs6888304 31,056,278 G/A 0.74 2.7 (2.0–3.5) 1.2 × 
10
−9
 
CDH6
n
 
5q11 rs4074793 52,228,882 A/G 0.07 5.5 (3.3–7.7) 3.4 × 
10
−10
 
ITGA1
n
 
6p12 rs9296736 54,032,656 C/T 0.31 3.0 (2.1–4.0) 2.6 × 
10
−9
 
MLIP
ne
 
7q11 rs17145750 72,664,314 T/C 0.86 4.5 (2.9–6.3) 2.9 × 
10
−9
 
MLXIPL
nce
 
10q23 rs754466 79,350,440 A/T 0.24 3.5 (2.2–4.8) 6.4 × 
10
−10
 
DLG5
n
 
12q24
a
 rs7310409 119,909,244 A/G 0.59 6.8 (5.7–7.8) 7.0 × 
10
−45
 
HNF1A
nc
, C12orf27
e
 
14q32 rs944002 102,642,568 A/G 0.21 6.3 (4.9–7.7) 5.8 × 
10
−29
 
C14orf73
nc
 
15q21 rs339969 58,670,573 C/A 0.62 4.5 (3.9–5.1) 6.6 × 
10
−20
 
RORA
n
 
15q23 rs8038465 71,765,390 C/T 0.39 2.4 (1.8–3.0) 1.4 × 
10
−9
 
CD276
ne
 
16q23 rs4581712 79,055,102 C/A 0.27 3.2 (2.5–3.9) 3.1 × 
10
−9
 
DYNLRB2
n
 
17q24 rs9913711 67,609,756 G/C 0.65 2.4 (1.8–3.0) 1.3 × 
10
−9
 
FLJ37644
e
, SOX9
n
 
18q21.31 rs12968116 53,473,500 T/C 0.87 4.8 (2.8–6.7) 8.9 × 
10
−10
 
ATP8B1
ncg
 
Region 
Sentinel 
SNP Position 
Alleles 
(R/E) EAF 
Effect (%, 95% 
confidence 
interval) P Genes of interest 
18q21.32 rs4503880 54,235,034 C/T 0.21 3.6 (2.5–4.7) 3.0 × 
10
−12
 
NEDD4L
n
 
19q13
a
 rs516246 53,897,984 C/T 0.47 2.3 (1.8–2.9) 7.6 × 
10
−10
 
FUT2
nc
 
22q11.21 rs1076540 16,819,958 T/C 0.78 4.8 (3.5–6.1) 9.6 × 
10
−17
 
MICAL3
ne
 
22q11.23 rs2739330 22,625,286 C/T 0.42 3.7 (2.7–4.6) 1.7 × 
10
−9
 
DDT
e
, DDTL
e
, 
GSTT1
e
, GSTT2B
n
, 
MIF
e
 
22q11.23
a
 rs2073398 23,329,104 C/G 0.34 12.3 (10.9–13.7) 1.1 × 
10
−109
 
GGT1
ne
, GGTLC2
e
 
Alleles are given as the reference (R) allele/effect (E). EAF, effect allele frequency; effect is change 
in concentration of liver enzyme in plasma per copy of effect allele. 
a
Previously reported associations. Annotation for genes of interest: 
n
nearest; 
e
expression QTL; 
c
coding SNP; 
g
GRAIL; 
o
known biology. 
  
Fig3 
Association of FADS1, FADS2, GCKR, HNF1A, TRIB1 and PPP1R3B loci with NMR metabonome. Bars are for –
log10 P value, signed for direction of effect. 
 
 
